Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Platinum-Resistant ovarian cancer: experimental drug ubamatamab enters phase 2 trials

NCT ID NCT06787612

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 6 times

Summary

This phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how safe and effective these combinations are, and how they affect tumor growth and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ubamatamab (a bispecific antibody that targets cancer cells and immune cells)
What this could lead to
If successful, this could provide a new treatment option for people with ovarian cancer that no longer responds to platinum-based chemotherapy.
What could go wrong
This is a phase 2 trial, so it is still early. The drug may not work as hoped, and side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 297 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian (regardless of the grade), primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded) 2. Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4. Adequate organ and bone marrow function, as described in the protocol 5. Platinum-Resistant Ovarian Cancer, as described in the protocol Key Exclusion Criteria: 1. Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study intervention(s) 2. Documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study intervention(s) 3. Another malignancy that is progressing or requires active treatment, as described in the protocol 4. Untreated or active Central Nervous System (CNS) metastases, or carcinomatous meningitis, as described in the protocol 5. Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency 6. Moderate to large or ascites, as described in the protocol 7. Bowel obstruction within last 3 months or current need for parenteral nutrition NOTE: Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube cancer Ovarian cancer Primary peritoneal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    56 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advent Health Cancer Institute

    RECRUITING

    Orlando, Florida, 32804, United States

  • Ankara Bilkent City Hospital

    RECRUITING

    Ankara, 06200, Turkey (Türkiye)

  • Asan Medical Center, Univ. of Ulsan

    RECRUITING

    Seoul, 05505, South Korea

  • Avera Cancer Institute Sioux Falls

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

  • Baskent University

    RECRUITING

    Adana, 01123, Turkey (Türkiye)

  • CancerCare Manitoba

    RECRUITING

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Cedars Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

  • Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval

    RECRUITING

    Québec, G1J 0J9, Canada

  • Centre de Santé et de Services Sociaux de la Montérégie-Centre

    RECRUITING

    Greenfield Park, Quebec, J4V 2H1, Canada

  • Cerrahpasa Medical Faculty At Istanbul University Cerrahpasa

    RECRUITING

    Istanbul, 34450, Turkey (Türkiye)

  • Changhua Christian Hospital

    RECRUITING

    Changhua, Changhua City, 500, Taiwan

  • Chi Mei Medical Center

    RECRUITING

    Tainan, 71004, Taiwan

  • Ege Universitesi Tip Fakultesi Hastanesi

    RECRUITING

    Bornova, İzmir, 35100, Turkey (Türkiye)

  • Gachon University Gil Medical Center

    RECRUITING

    Incheon, Seoul, 21565, South Korea

  • Gangnam Severance Hospital

    RECRUITING

    Seoul, 135-720, South Korea

  • Gaziantep Medicalpoint Hospital

    RECRUITING

    Gaziantep, Sehitkamil, 27584, Turkey (Türkiye)

  • Hacettepe University

    RECRUITING

    Altındağ, Ankara, 06240, Turkey (Türkiye)

  • Izmir Ekonomi Universitesi (IEU) Medical Point Izmir Hastanesi (Izmir Economy University Medical Point Izmir Hospital)

    RECRUITING

    Izmir, 35575, Turkey (Türkiye)

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Keimyung University Dongsan Hospital

    RECRUITING

    Daegu, 42601, South Korea

  • Korea University Guro Hospital

    RECRUITING

    Seoul, 8308, South Korea

  • Mackay Memorial Hospital

    RECRUITING

    Taipei, 10449, Taiwan

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Jacksonville

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Medicalpark Seyhan Hospital

    RECRUITING

    Seyhan, Adana, 01140, Turkey (Türkiye)

  • Medipol University Hospital

    RECRUITING

    Istanbul, Bagcilar, 34284, Turkey (Türkiye)

  • Memorial Ankara Hospital

    RECRUITING

    Ankara, 0906520, Turkey (Türkiye)

  • National Cancer Center

    RECRUITING

    Gyeonggi-do, Gyeonggi-do, 10408, South Korea

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 106, Taiwan

  • Norton Cancer Institute, St. Matthews Clinic

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Providence Cancer Institute

    RECRUITING

    Portland, Oregon, 97213, United States

  • Research Institute - McGill University Health Centre

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Sakarya University - Education and Research Hospital

    RECRUITING

    Sakarya, 54290, Turkey (Türkiye)

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji Suam

    RECRUITING

    Ankara, 06100, Turkey (Türkiye)

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 3080, South Korea

  • Severance Hospital Yonsei University Health System

    RECRUITING

    Seoul, 03722, South Korea

  • Swedish Cancer Institute

    RECRUITING

    Seattle, Washington, 98104, United States

  • Taipei Municipal Wan Fang Hospital

    RECRUITING

    Taipei, 116, Taiwan

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11211, Taiwan

  • Tampa General Hospital Cancer Institute

    RECRUITING

    Tampa, Florida, 33606, United States

  • The Ohio State University Comprehensive Cancer Center

    RECRUITING

    Hilliard, Ohio, 43026, United States

  • The University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • The University of Kansas Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • Tri-Service General Hospital

    RECRUITING

    Taipei, 114202, Taiwan

  • UC San Diego Health

    RECRUITING

    La Jolla, California, 92037, United States

  • UT Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Pittsburgh Medical Center, Magee-Womens Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • West Penn Hospital of Allegheny Health Network

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.